INTRODUCTION We compared the salivary immunoglobulin A (IgA) and lysozyme concentration and secretion rates among mild and severe psoriasis patients and controls in Singapore. MATERIALS AND METHODS Fifty-one psoriasis patients and 24 controls participated in the study. None of the patients were on immunosuppressive therapy. The Psoriasis Area and Severity Index (PASI) was used to assess the s...

In the last two months, he has a dry desquamative EP (PASI: 32.8) with arthritis of both ankles. Laboratory test before biologic treatment were normal. He received subcutaneous injection of etanercept 50mg × 2 / week. At week 12, a clinical improvement in the patient condition was observed. Erythematic, scaling and itching showed a rapid response, with significantly reducing the PASI score to 7...

Sir, A 60‐year‐old Japanese man with a 30‐year history of psoriasis vulgaris was referred to our hospital. His previous treatments, including topical corticosteroids, Vitamin D analogs, narrowband ultraviolet B, and cyclosporine, demonstrated poor disease control. At his first visit, he presented with scaly erythematous plaques on his trunk, extremities, and scalp, with considerable itching. At...

BACKGROUND Psoriasis is associated with a deterioration in the health-related quality of life (HRQoL) of affected patients. The aim of this study was to assess the HRQoL of patients with moderate-to-severe psoriasis. METHODS A prospective observational study (the VACAP Study) was carried out in 123 centers in Spain with 1217 patients. Patients were evaluated at baseline (visit 1 [V1]) and aga...

The objective of this study was to assess the effectiveness of a specific composition of a traditional herbal preparation (DurrDerma) in adult patients with moderate to severe skin psoriasis. The preparation is a newly developed topical combination containing plant-based extracts traditionally used in skin disease as black cumin, olive oil, tea tree oil, cocoa butter completed by vitamin A and ...

There are limited data on the safety and efficacy of switching to secukinumab from cyclosporine A (CyA) in patients with psoriasis. The purpose of the present study was to assess the efficacy and safety of secukinumab for 16 weeks after direct switching from CyA in patients with moderate-to-severe psoriasis. In this multicenter, open-label, phase IV study, 34 patients with moderate-to-severe ps...

OBJECTIVE To investigate the efficacy and safety outcomes of combination therapy used to optimize etanercept treatment in patients with psoriasis treated in real-life clinical practice. METHODS Data from patients presenting with psoriasis, treated initially with etanercept monotherapy, were analysed retrospectively. Patients subsequently treated with combination therapy were further analysed....

The safety and efficacy of adalimumab were evaluated over 24 weeks in Japanese patients with psoriasis in routine clinical practice. In this multicenter, observational, open-label, postmarketing study, primary efficacy measures included the Psoriasis Area and Severity Index (PASI) and the Dermatology Life Quality Index (DLQI) in all patients with psoriasis. In patients with psoriatic arthritis ...

BACKGROUND Apremilast, an oral phosphodiesterase 4 inhibitor, has an acceptable safety profile and is effective for treatment of plaque psoriasis and psoriatic arthritis. OBJECTIVES To evaluate the impact of apremilast on health-related quality of life (HRQOL), general functioning and mental health using patient-reported outcome (PRO) assessments among patients with moderate to severe plaque ...